Dyax sales and marketing update

Dyax launched a refund program for patients receiving diagnostic testing for hereditary angioedema (HAE). Patients who do not have health insurance coverage or have a copay, coinsurance or deductible for HAE diagnostic testing are eligible to have expenses refunded. Those not eligible include patients enrolled in any government healthcare program, such as Medicare, Medicaid or Tricare, and patients residing in Massachusetts, Michigan, Minnesota or Rhode Island. Dyax markets Kalbitor ecallantide, a subcutaneously delivered yeast-derived recombinant plasma kallikrein inhibitor, to treat HAE in the U.S. Last November, Dyax withdrew an MAA in Europe for Kalbitor in the indication because EMA's CHMP indicated that the information provided was not sufficient to demonstrate a positive benefit-risk balance (see BioCentury, Nov. 21, 2011). ...